CA2314683A1 - Emploi therapeutique de vecteurs lentiviraux - Google Patents

Emploi therapeutique de vecteurs lentiviraux Download PDF

Info

Publication number
CA2314683A1
CA2314683A1 CA002314683A CA2314683A CA2314683A1 CA 2314683 A1 CA2314683 A1 CA 2314683A1 CA 002314683 A CA002314683 A CA 002314683A CA 2314683 A CA2314683 A CA 2314683A CA 2314683 A1 CA2314683 A1 CA 2314683A1
Authority
CA
Canada
Prior art keywords
vector
cells
hiv
gene
transgene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002314683A
Other languages
English (en)
Inventor
Luigi Naldini
Jin-Ping Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Genesys Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2314683A1 publication Critical patent/CA2314683A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur un vecteur lentiviral inhibant la propagation d'un lentivirus dans une cellule.
CA002314683A 1997-12-12 1998-12-11 Emploi therapeutique de vecteurs lentiviraux Abandoned CA2314683A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6957997P 1997-12-12 1997-12-12
US60/069,579 1997-12-12
PCT/US1998/025720 WO1999030742A1 (fr) 1997-12-12 1998-12-11 Emploi therapeutique de vecteurs lentiviraux

Publications (1)

Publication Number Publication Date
CA2314683A1 true CA2314683A1 (fr) 1999-06-24

Family

ID=22089926

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002314683A Abandoned CA2314683A1 (fr) 1997-12-12 1998-12-11 Emploi therapeutique de vecteurs lentiviraux

Country Status (6)

Country Link
EP (1) EP1037669A4 (fr)
JP (1) JP2002508338A (fr)
KR (1) KR20010033062A (fr)
AU (1) AU749059B2 (fr)
CA (1) CA2314683A1 (fr)
WO (1) WO1999030742A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
CA2408328C (fr) 2000-05-10 2012-04-17 Aventis Pasteur Limited Polypeptides immunogeniques codes par des minigenes mage et leurs utilisations
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
EP1594459B1 (fr) 2002-12-30 2010-02-17 Angiotech International Ag Liberation de medicaments a partir d'une composition polymere a gelification rapide
CA2523138C (fr) 2003-04-24 2013-04-23 Fondazione Centro San Raffaele Del Monte Tabor Vecteurs lentiviraux portant des promoteurs bidirectionnels de synthese, et leurs utilisations
WO2009049351A1 (fr) 2007-10-15 2009-04-23 The University Of Queensland Système de construction et utilisations pour celui-ci
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
AU2016367712B2 (en) 2015-12-09 2021-10-07 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
WO2018018082A1 (fr) 2016-07-26 2018-02-01 The Australian National University Compositions immunostimulantes et utilisations de celles-ci

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3325579B2 (ja) * 1995-03-16 2002-09-17 久光製薬株式会社 新規遺伝子組換え体
US5650309A (en) * 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU1123497A (en) * 1995-11-28 1997-06-19 Clinical Technologies, Inc. Recombinant hiv and modified packaging cells and method for treating acquired immune deficiency syndrome
CN1651577A (zh) * 1995-11-28 2005-08-10 约翰斯·霍普金斯大学医学院 条件复制型病毒载体及其用法
AP964A (en) * 1996-02-21 2001-05-11 Julianna Lisziewicz Methods and compositions for protective and therapeutic genetic immunisation.
CA2247091A1 (fr) * 1996-03-05 1997-09-12 The Regents Of The University Of California Virus de l'immunodeficience feline vivants recombines et vaccins d'adn proviraux
DE69737597D1 (de) * 1996-07-22 2007-05-24 Us Gov Health & Human Serv Vektoren zur inhibierung von viralem und tumorwachstum
US20020123471A1 (en) * 1997-03-06 2002-09-05 Klaus Uberla Lentivirus based vector and vector system
GB9704977D0 (en) * 1997-03-11 1997-04-30 Univ Glasgow FIV vaccine
EP1003894A2 (fr) * 1997-07-18 2000-05-31 Chiron Corporation Vecteurs lentiviraux

Also Published As

Publication number Publication date
EP1037669A1 (fr) 2000-09-27
JP2002508338A (ja) 2002-03-19
AU1803599A (en) 1999-07-05
WO1999030742A1 (fr) 1999-06-24
EP1037669A4 (fr) 2003-04-02
KR20010033062A (ko) 2001-04-25
AU749059B2 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
JP4190579B2 (ja) 非***細胞への核酸運搬のためのベクターおよび使用方法
US9260725B2 (en) Methods and compositions relating to improved lentiviral vector production systems
JP4390860B2 (ja) レンチウイルスをベースにした遺伝子転移ベクター
US5635399A (en) Retroviral vectors expressing cytokines
US20180251786A1 (en) Recombinant vectors comprising 2a peptide
CA2328404C (fr) Nouvelles cellules lentivirales d'encapsidation
KR20010033064A (ko) 높은 역가를 갖는 안전한 재조합 렌티바이러스 벡터를생성시키는 방법 및 수단
WO1997012622A9 (fr) Vecteur et procede permettant d'alimenter en acide nucleique des cellules ne subissant pas de division
JPH10507905A (ja) ヒト血清による溶解耐性生産者細胞系で生産されるレトロウイルスベクター
JP2002518997A (ja) レトロウイルス送達システム
US20140170709A1 (en) Vector for gene therapy
AU749059B2 (en) Therapeutic use of lentiviral vectors
EP0970201A1 (fr) Vecteurs retroviraux pouvant transduire des cellules ne se divisant pas
US6130089A (en) Materials and methods for gene transfer
DE69829174T2 (de) Exprimierung eines modifiziertem "foamy virus envelope protein" (hüllenprotein)
CA2233867C (fr) Vecteur et procede permettant d'alimenter en acide nucleique des cellules ne subissant pas de division
AU758600B2 (en) Vector and method of use for nucleic acid delivery to non-dividing cells
Joseph Non-integrating integrase and long terminal repeat attachment site mutant HIV-1-derived lentiviral vectors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead